Insider Buying: Immunome (NASDAQ:IMNM) Director Acquires $103,500.00 in Stock

Immunome, Inc. (NASDAQ:IMNM) Director Jean Jacques Bienaime bought 5,000 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The shares were acquired at an average cost of $20.70 per share, for a total transaction of $103,500.00. Following the completion of the purchase, the director owned 43,415 shares in the company, valued at $898,690.50. This trade represents a 13.02% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Jean Jacques Bienaime also recently made the following trade(s):

• On Wednesday, March 11th, Jean Jacques Bienaime purchased 1,000 shares of Immunome stock. The stock was acquired at an average cost of $21.55 per share, with a total value of $21,550.00.

Immunome Stock Down 4.7%

NASDAQ:IMNM opened at $19.90 on Tuesday. Immunome, Inc. has a 52 week low of $7.74 and a 52 week high of $27.65. The company has a fifty day simple moving average of $21.94 and a two-hundred day simple moving average of $21.24. The company has a market cap of $2.25 billion, a price-to-earnings ratio of -8.36 and a beta of 2.11.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.60) by $0.12. On average, analysts expect that Immunome, Inc. will post -2.26 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on IMNM. Wall Street Zen raised Immunome from a “sell” rating to a “hold” rating in a research report on Saturday. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Immunome in a report on Wednesday, May 13th. Leerink Partners decreased their price target on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a research note on Friday. Craig Hallum boosted their price target on shares of Immunome from $33.00 to $36.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. Finally, Stephens dropped their price objective on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 4th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $32.82.

Hedge Funds Weigh In On Immunome

Several large investors have recently bought and sold shares of the stock. Nan Fung Trinity HK Ltd. lifted its holdings in shares of Immunome by 7.9% in the 3rd quarter. Nan Fung Trinity HK Ltd. now owns 592,103 shares of the company’s stock valued at $6,934,000 after purchasing an additional 43,253 shares during the last quarter. NEOS Investment Management LLC boosted its position in shares of Immunome by 40.5% in the 3rd quarter. NEOS Investment Management LLC now owns 162,186 shares of the company’s stock valued at $1,899,000 after purchasing an additional 46,755 shares during the period. Pivotal bioVenture Partners Investment Advisor LLC purchased a new position in Immunome during the 3rd quarter worth approximately $5,884,000. TD Asset Management Inc grew its stake in Immunome by 15.8% during the 3rd quarter. TD Asset Management Inc now owns 701,280 shares of the company’s stock worth $8,212,000 after buying an additional 95,750 shares during the last quarter. Finally, Principal Financial Group Inc. increased its position in Immunome by 222.3% during the third quarter. Principal Financial Group Inc. now owns 1,104,938 shares of the company’s stock worth $12,939,000 after buying an additional 762,147 shares during the period. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.